Literature DB >> 16570180

Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma.

Anna Batistatou1, Alexander K Charalabopoulos, Chrisoula D Scopa, Yukihiro Nakanishi, Angelos Kappas, Setsuo Hirohashi, Niki J Agnantis, Konstantinos Charalabopoulos.   

Abstract

Reduction/loss of E-cadherin is associated with the development and progression of many epithelial tumors, while in a limited number of neoplasms, E-cadherin is re-expressed in metastases. Dysadherin, recently characterized by members of our research team, has an anti-cell-cell adhesion function and downregulates E-cadherin in a posttranscriptional manner. Colorectal cancer (CRC) is one of the most common tumors in the developed world, and lymph node metastases are harbingers of aggressive behavior. The aim of the present study was to examine the dysadherin and E-cadherin expression patterns in lymph node metastases vs primary CRC. Dysadherin and E-cadherin expression was examined immunohistochemically in 78 patients with CRC, Dukes' stage C in the primary tumor and in one lymph node metastasis. Dysadherin was expressed in 42% while E-cadherin immunoreactivity was reduced in 45% of primary tumors. In lymph nodes, 33 and 81% of metastatic tumors were positive for dysadherin and E-cadherin, respectively. Dysadherin expression was not correlated with E-cadherin expression in the primary tumor with a reverse correlation evident in the lymph node metastases. Our results suggest that different mechanisms govern E-cadherin expression in the primary tumor and the corresponding lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570180     DOI: 10.1007/s00428-006-0183-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  36 in total

1.  Utility of MMP-1, p53, E-cadherin, and collagen IV immunohistochemical stains in the differential diagnosis of adenomas with misplaced epithelium versus adenomas with invasive adenocarcinoma.

Authors:  Rhonda K Yantiss; Marcus W Bosenberg; Donald A Antonioli; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2002-02       Impact factor: 6.394

2.  Survival after curative resection of lymph node negative colorectal carcinoma. A prospective study of 910 patients.

Authors:  R C Newland; O F Dent; P H Chapuis; L Bokey
Journal:  Cancer       Date:  1995-08-15       Impact factor: 6.860

3.  Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis.

Authors:  Erminia Massarelli; Erika Brown; Ngoc K Tran; Diane D Liu; Julie G Izzo; J Jack Lee; Adel K El-Naggar; Waun K Hong; Vassiliki A Papadimitrakopoulou
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

4.  Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases.

Authors:  Yukihiro Nakanishi; Shingo Akimoto; Yasuto Sato; Yae Kanai; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2004-12

5.  Role of E-cadherins in development of lymphatic tumor emboli.

Authors:  Anita Gupta; Charuhas G Deshpande; Sunil Badve
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

6.  Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.

Authors:  Aya Nishizawa; Yukihiro Nakanishi; Kimio Yoshimura; Yuko Sasajima; Naoya Yamazaki; Akifumi Yamamoto; Katsumi Hanada; Yae Kanai; Setsuo Hirohashi
Journal:  Cancer       Date:  2005-04-15       Impact factor: 6.860

Review 7.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

Authors:  S Hirohashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Role of E-cadherin in the response of tumor cell aggregates to lymphatic, venous and arterial flow: measurement of cell-cell adhesion strength.

Authors:  S W Byers; C L Sommers; B Hoxter; A M Mercurio; A Tozeren
Journal:  J Cell Sci       Date:  1995-05       Impact factor: 5.285

9.  E-cadherin expression in primary and metastatic thoracic neoplasms and in Barrett's oesophagus.

Authors:  P F Bongiorno; M al-Kasspooles; S W Lee; W J Rachwal; J H Moore; R I Whyte; M B Orringer; D G Beer
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

10.  E-cadherin expression in primary carcinomas of the breast and its distant metastases.

Authors:  Paul J Kowalski; Mark A Rubin; Celina G Kleer
Journal:  Breast Cancer Res       Date:  2003-09-26       Impact factor: 6.466

View more
  16 in total

1.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression.

Authors:  Y Li; J H Bavarva; Z Wang; J Guo; C Qian; S N Thibodeau; E A Golemis; W Liu
Journal:  Oncogene       Date:  2011-02-14       Impact factor: 9.867

2.  Site-dependent E-cadherin cleavage and nuclear translocation in a metastatic colorectal cancer model.

Authors:  María Virtudes Céspedes; María Jesús Larriba; Miguel Angel Pavón; Patricia Alamo; Isolda Casanova; Matilde Parreño; Anna Feliu; Francesc Josep Sancho; Alberto Muñoz; Ramón Mangues
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

Review 3.  Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.

Authors:  Lorena Losi; Tommaso Zanocco-Marani; Alexis Grande
Journal:  Histol Histopathol       Date:  2020-06-22       Impact factor: 2.303

Review 4.  Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer.

Authors:  Alexandros Georgolios; Anna Eleftheriadou; Anna Batistatou; Kostandinos Charalabopoulos
Journal:  Med Oncol       Date:  2011-11-22       Impact factor: 3.064

5.  Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer.

Authors:  Kirk Jensen; Aneeta Patel; Victoria Hoperia; Alexander Larin; Andrew Bauer; Vasyl Vasko
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

6.  Parathormone and 1,25(OH)2D3 but not 25(OH)D3 serum levels, in an inverse correlation, reveal an association with advanced stages of colorectal cancer.

Authors:  Anestis Charalampopoulos; Alexander Charalabopoulos; Anna Batistatou; Christos Golias; Antonia Anogeianaki; Dimitrios Peschos; Iosif Iliadis; Anastasios Macheras; Konstantinos Charalabopoulos
Journal:  Clin Exp Med       Date:  2009-09-25       Impact factor: 3.984

7.  Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.

Authors:  Anna Batistatou; Konstantinos Charalabopoulos; Yukihiro Nakanishi; Constantine Vagianos; Setsuo Hirohashi; Niki J Agnantis; Chrissoula D Scopa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

8.  Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.

Authors:  S M Brouxhon; S Kyrkanides; X Teng; M Athar; S Ghazizadeh; M Simon; M K O'Banion; L Ma
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

9.  Alterations in dysadherin expression and F-actin reorganization: a possible mechanism of hypericin-mediated photodynamic therapy in colon adenocarcinoma cells.

Authors:  Aysun Kılıç Süloğlu; Güldeniz Selmanoğlu; M Turan Akay
Journal:  Cytotechnology       Date:  2014-02-08       Impact factor: 2.058

Review 10.  Dysadherin: a new player in cancer progression.

Authors:  Jeong-Seok Nam; Setsuo Hirohashi; Lalage M Wakefield
Journal:  Cancer Lett       Date:  2007-04-17       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.